0000950170-24-002278.txt : 20240104
0000950170-24-002278.hdr.sgml : 20240104
20240104214738
ACCESSION NUMBER: 0000950170-24-002278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240102
FILED AS OF DATE: 20240104
DATE AS OF CHANGE: 20240104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McNeill Jonathan
CENTRAL INDEX KEY: 0001824673
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39509
FILM NUMBER: 24514342
MAIL ADDRESS:
STREET 1: C/O DYNE THERAPEUTICS, INC.
STREET 2: 830 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Dyne Therapeutics, Inc.
CENTRAL INDEX KEY: 0001818794
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 364883909
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: (781) 786-8230
MAIL ADDRESS:
STREET 1: 1560 TRAPELO ROAD
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
ownership.xml
4
X0508
4
2024-01-02
0001818794
Dyne Therapeutics, Inc.
DYN
0001824673
McNeill Jonathan
1560 TRAPELO ROAD
WALTHAM
MA
02451
false
true
false
false
Chief Business Officer
true
Common Stock
2024-01-02
4
S
false
11900
13.10
D
143618
D
Common Stock
2024-01-03
4
M
false
17991
0.73
A
161609
D
Common Stock
2024-01-03
4
S
false
7691
18.34
D
153918
D
Common Stock
2024-01-03
4
S
false
10300
19.03
D
143618
D
Common Stock
2024-01-04
4
M
false
2009
0.73
A
145627
D
Common Stock
2024-01-04
4
S
false
2009
18.04
D
143618
D
Stock option (right to buy)
0.73
2024-01-03
4
M
false
17991
0
D
2029-02-25
Common Stock
17991
50537
D
Stock option (right to buy)
0.73
2024-01-04
4
M
false
2009
0
D
2029-02-25
Common Stock
2009
48528
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.76 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes of this Form 4.
Includes 143,067 unvested RSUs.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.50, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.00 to $19.25, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.07, inclusive.
The option was granted on February 26, 2019. The shares underlying the option vest over four years, with 25% of the shares vesting on February 1, 2020 and the remaining shares vesting in equal quarterly installments thereafter.
/s/ Richard Scalzo, Attorney-in-Fact
2024-01-04